Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Givosiran, for the Treatment of Acute Hepatic Porphyria Transcript
Good afternoon, and thank you for joining us for this RNAi Roundtable. Today, we'll be discussing givosiran for the treatment of acute hepatic porphyria. I'm Josh Brodsky, Senior Director of Investor Relations and Corporate Communications at Alnylam. With me today are Akin Akinc, General Manager of the givosiran program; Marianne Sweetser, Senior Distinguished Fellow in Clinical Development; and Laurent Placidi, Senior Director of Global Marketing for givosiran.
Today's RNAi Roundtable is the third in a series of roundtable webinars that we're hosting this summer and fall to review progress across our various programs. Today's event is expected to run approximately 60 to 75 minutes. Akin will moderate the Q&A session at the conclusion of the presentations. (Operator Instructions)
Finally, as a reminder, we'll be making forward-looking statements during this webinar, and we encourage you to read our most recent SEC filings for a more complete discussion of risk factors.
And with
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
